Highlights

  • Third quarter Revenue rose 3% to USD 1,624.9 million, and Net Income reached USD 63.4 million against USD 1.2 million.
  • Diluted earnings per share were USD 0.31 against a loss of USD 0.17, as salaries and benefits fell 4%.
  • Cash and cash equivalents rose to USD 766.2 million from USD 709.6 million at the end of 2025.
  • Management raised the low end of its 2026 adjusted EBITDA outlook to USD 500 million, keeping the top at USD 535 million.

Ardent Health, Inc. (NYSE:ARDT) shares were trading near their 52-week high at USD 17.30 on November 6, 2026, up 8.81%. The hospital operator announced an agreement to divest its Kansas hospital ownership to its joint venture partner in the third quarter, raised the low end of its 2026 adjusted EBITDA outlook, and reported third quarter results on November 5.

Based in Brentwood, Tennessee, Ardent was formed in Delaware in 2015 and converted into a Delaware corporation in July 2024 in connection with its initial public offering. The holding company's affiliates operate acute care hospitals and other healthcare facilities and employ physicians, and at September 30, 2026 the company operated 30 acute care hospitals in six states, including one managed hospital, two rehabilitation hospitals and two surgical hospitals. It leases 10 of its hospitals from Ventas under a master lease. Ardent has a market Capitalization of USD 2.44 billion and a price to earnings ratio of 31.49, and its fiscal year ends December 31.

Third Quarter Results

Total revenue was USD 1,624.9 million against USD 1,576.7 million a year earlier. Salaries and benefits fell to USD 647.9 million from USD 677.0 million, while professional fees rose to USD 327.8 million from USD 305.1 million and supplies rose to USD 283.1 million from USD 275.9 million. Other operating expenses dropped to USD 162.8 million from USD 198.7 million.

Income before income taxes was USD 81.0 million against a loss of USD 2.2 million, and the prior year quarter included a USD 7.3 million loss on Debt extinguishment and modification. Net income was USD 63.4 million, of which USD 18.9 million went to noncontrolling interests, leaving USD 44.5 million attributable to Ardent against a loss of USD 23.5 million.

For the nine months, revenue was USD 4,849.0 million against USD 4,719.3 million. Net income attributable to Ardent rose to USD 101.3 million from USD 90.9 million, or USD 0.71 per diluted share against USD 0.64, while other non-operating gains shrank to USD 6.9 million from USD 23.3 million.

Volumes, Payer Mix and Cost Programs

Management said adjusted EBITDA, a non-GAAP measure, was USD 138 million. Adjusted admissions grew 2.9%, emergency room visits rose 1.7%, and surgeries fell 1.9%, with half of the surgical decline coming from the planned exit of certain lower-margin service lines. Exchange admissions declined 7% and self-pay admissions rose by a similar amount.

The company's IMPACT program remains on track to deliver at least USD 70 million of savings in 2026. Management said it is 85% contracted for 2027 and 75% for 2028, and described payer negotiations as more contentious this year.

Cash Flow, Balance Sheet and Capital Returns

Management reported operating Cash Flow of USD 122 million for the quarter and USD 258 million for the nine months, despite a USD 37 million New Mexico supplemental access payment that arrived in early October. Total Assets were USD 5,353.0 million, total liabilities were USD 3,571.3 million, and total Equity was USD 1,789.0 million. Management put total debt at USD 1.1 billion and net Leverage at 0.8 times.

Ardent repurchased USD 11 million of stock in the quarter, and the board added USD 25 million to the program, leaving USD 48 million of authorization.

Outlook

Management raised the low end of its 2026 adjusted EBITDA range to USD 500 million from USD 485 million and kept the top at USD 535 million. It remains biased toward the low end of its USD 6.4 billion to USD 6.7 billion revenue range and trimmed its Capital Expenditure range to USD 210 million to USD 250 million from USD 225 million to USD 265 million.